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Low-molecular-weight heparins in prophylaxis and 
therapy of thromboembolic diseases 
Henri Bounemeaux, New York, 1994, Marcel Dekker, 
Inc., 323 pages, $125. 
The advent of low-molecular weight (LMW) heparins 
has generated considerable xcitement in all fields of 
medicine. The book Low-Molecular-Weight Heparins in 
Prophylaxis and Therapy of Thromboembolic Disease is a 
~orough introduction to these remarkable therapeutic 
agents. 
LMW heparins are derived from standard heparin by 
chemical means. These lower-weight fractions have mul- 
tiple advantages over standard heparin, including less 
platelet interactions, improved pharmacokinetics, im- 
proved safety, standard dosing, and even a potential 
anticancer effect. Although most of the published clinical 
research as concerned use of LMW heparins in prophy- 
laxis of deep venous thrombosis, the appeal of outpatient 
therapy has engendered enthusiasm concerning the use of 
LMW in therapy of thrombosis. 
The first part of this book is an introduction to basic 
issues concerning all LMW heparins, including the prob- 
lems raised in measuring plasma levels, given that most 
LMW heparins do not raise the activated partial thrombo- 
plastin time. A highlight of this text is Drs. Warkentin and 
Kelton's chapter on the interaction of heparin with 
platelets. This chapter is an excellent review of heparin- 
induced thrombocytopenia (HIT) by two leaders in the 
field. They emphasize the fact that, although the incidence 
of H IT  may decreased with LMW heparin, LMW heparin 
cannot be used in patients with established HIT  because of 
cross-reactiviry between the two agents. One can use 
heparinoids that, like heparin, act as a cofactor for 
antithrombin II I  but do not (in most patients) cross-react 
with H IT  antibodies. 
The major part of the book is a compendium of clinical 
trials of LMW heparins for a variety of clinical situations. 
Most clinical trials have been for prophylaxis of deep 
venous thrombosis. All the chapters attempt to summarize 
and place in perspective the multitude of trials performed 
with LMW heparins. These data document the evidence of 
the usefulness of LMW heparin in all types of patients. 
These compounds have been especially useful in patients 
undergoing orthopedic surgery because the compounds are 
easier to dose and use than adjusted-dose heparin or 
warfarin. These chapters are a valuable resource for anyone 
wanting to research the uses of LMW heparins. 
The most exciting use of LMW heparins is as therapy 
for established thrombosis. The few trials performed to 
date show both a reduction in hemorrhagic complications 
and a reduction in the overall mortality rate in patients with 
cancer. 
This book deals frankly with the remaining questions 
concerning LMW heparin. In the era of short hospital stays, 
the problem of outpatient deep venous thrombosis is 
increasing, and this may be another prophylactic role for 
LMW heparins. Despite the many trials performed with 
LMW, very few have tested different LMW heparins 
head-to-head. This raises the fear that soon the clinician will 
be faced with multiple LMW heparins to choose from, all 
for the same problem. This is a situation not unlike 
cephalosporin antibiotics or beta-blockers. 
I highly recommend this book to any physician seeking 
additional knowledge about these agents and their poten- 
tial use. 
Thomas DeLoughery, MD 
Oregon Health Sciences University 
Portland, Ore. 
Stroke: Populations, cohorts, and clinical traits 
Jack P. Whisnant, Oxford, 1993, Butterworth-Heine- 
mann, 263 pages, $65. 
This book has contributions from a variety of authors 
who are neurologists, epidemiologists, rehabilitation ex- 
perts, and biostatisticians, and the contributions come from 
North America, New Zealand, and Japan, with a couple of 
contributions from Scandinavia. 
The title topic is timely for vascular surgeons who must 
now show an interest in clinical trials in stroke and so must 
understand population methods, cohorts, and selections 
for trials and methods by which the results are claimed. Not 
least the vascular surgeon needs to be able to assess the 
validity of claims from these trials. The book is an excellent 
source of references for the surgeon interested in the 
performance ofcarotid and vertebral artery surgery, but the 
book does not read easily in chapters, such as Chapter 7 on 
attributal risk. Chapters uch as those on natural history of 
transient ischemic and ischemic stroke by the editor are 
extremely usefi.fl background information for the vascular 
surgeon. 
On balance, this is not really a book for vascular 
surgeons, but one that they would appreciate seeing in a 
library for occasional reference. 
Roger M. G~eenhalgh, ME) 
Charing Cross Hospital 
London, United IGngdom 
General surgery 
Wallace P. Ritchie, Jr., Glenn Steele, Jr., Richard H. 
Dean, Philadelphia, 1994, JB Lippincott, 1008 pages, 
$149. 
It was the intent of the editors to provide the reader of 
this text a book that might be considered "no-nonsense 
general surgery." As such this is a clinical text that focuses 
on the important problems commonly treated by the 
practicing general surgeon. Herein one will not find 
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